Bristol Myers Squibb Company $BMY Holdings Lowered by Nordea Investment Management AB

Nordea Investment Management AB reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 61.5% in the fourth quarter, HoldingsChannel reports. The fund owned 200,318 shares of the biopharmaceutical company’s stock after selling 319,832 shares during the quarter. Nordea Investment Management AB’s holdings in Bristol Myers Squibb were worth $10,837,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb during the second quarter worth approximately $25,000. Harbor Capital Advisors Inc. boosted its stake in Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 313 shares in the last quarter. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Bristol Myers Squibb during the 3rd quarter valued at $35,000. JPL Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the 3rd quarter worth $36,000. Finally, Total Investment Management Inc. bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth $38,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 2.7%

Shares of Bristol Myers Squibb stock opened at $58.94 on Thursday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The firm has a market capitalization of $120.02 billion, a PE ratio of 17.08, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The stock’s fifty day moving average is $58.69 and its 200-day moving average is $52.06.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Analyst Ratings Changes

Several research analysts recently weighed in on BMY shares. Wells Fargo & Company reaffirmed an “outperform” rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Scotiabank restated a “sector perform” rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Barclays initiated coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective on the stock. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Nine research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and an average target price of $61.41.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.